VerifyNow P2Y12 assay: Pivotal trial additional data

A post hoc analysis of 2,796 patients in the double-blind, North American pivotal GRAVITAS trial showed that patients with platelet reactivity <208 P2Y12 reaction units (PRU) while on Plavix clopidogrel experienced a significantly lower risk of the cumulative incidence of CV death, non-fatal MI or stent thrombosis at 60 days (p=0.02) and throughout the 6-month trial (p=0.01). Patients with on-treatment reactivity <230 PRU did not experience a significant reduction in the risk of cardiovascular events (p=0.2). Data were presented at the European Society of Cardiology in Paris and published in Circulation. ...